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For many years, it has been accepted that the etiology of
early-onset Alzheimer’s disease (AD) is genetic in nature,
with the relevant mutations involving genes encoding prod-
ucts that function in pathways dealing with processing of
β-amyloid. The etiology of the far more prevalent late-
onset AD is not primarily genetic in origin even though
research over the last two decades has identiﬁed one or more
genetic risk factors that predispose their bearers to devel-
opment of the disease. Studies of late-onset AD have been
strongly inﬂuenced by the amyloid cascade hypothesis. This
inﬂuential hypothesis posits that plaques of β-amyloid (i.e.,
neuritic senile plaques, NSP) accumulate in the neuropil,
wheretheyeventuallyinitiateaneuropathogenicprocessthat
engenders production of insoluble tangles of modiﬁed tau
protein (i.e., neuroﬁbrillar tangles, NFT), the ultimate result
of which is progressive cognitive dysfunction. Firm and ﬁnal
diagnosis of the disease remains dependent on postmortem
quantitation of the density and character of NSP and NFT
in speciﬁc regions (e.g., hippocampus) of the aﬀected brain.
In addition, inﬂammation in the late-onset AD brain has
been well documented, but this potentially important aspect
of pathogenesis has not found a major place in the suite of
factors thought to play primary roles in the neuropathogenic
process.
Substantial evidence derived from clinical trials, animal
modelstudies,andothersourcesindicatesthatlate-onsetAD
cannotbeexplainedsolelyorprimarilybyaccumulatingNSP
and NFT despite the fact that these are the most obvious and
consistent pathological features of this disease. Rather, the
evidence strongly suggests that late-onset AD results from
a complex interplay between genetic and environmental
factors, most of which remain to be elucidated. In this
special issue, we were interested particularly in papers that
present alternative viewpoints concerning the complex eti-
ology and pathogenic processes underlying late-onset AD.
The solicitation targeted reports of primary research from
diﬀerent ﬁelds, including new genome sequence or structure
data that shed light on the complex genetic background
giving increased susceptibility to disease induction, new in-
sights regarding relevant environmental inﬂuences that may
contribute to that induction, and new studies focusing on
the biochemistry and molecular genetics of AD. Further,
we wanted review articles that summarized recent research
developments that engender new views on the etiology
and/or neuropathogenic mechanisms of AD as well as
hypothesis-driven but evidence-based arguments regarding
etiology and neuropathogenesis.
T h eﬁ r s tp a p e ri n c l u d e di nt h i ss p e c i a li s s u ep r e s e n t sa n
interesting, and we think cogent, argument for a reconsid-
eration of the amyloid cascade hypothesis. The authors of
this review conclude that current evidence indicates that the
production of NFT and NSP is independent of one another
and that these are probably the products, not the cause, of
the neurodegeneration that characterizes late-onset AD. The
article presents a modiﬁed version of the hypothesis that2 International Journal of Alzheimer’s Disease
provides a reasonable explanation of the pathogenesis of the
disease.
Since ﬁrm diagnosis of late-onset AD depends on
postmortem examination of the brain of aﬀected individuals,
a pressing need exists for identiﬁcation of markers that
can reliably indicate the presence of AD in individuals
at much earlier stages of the disease induction process.
The second paper included in this special issue presents
new research indicating that delineation of certain aspects
of the IL-10 genotype and expression of one membrane-
located adenosine receptor might prove useful in identifying
individuals with the early signs of dementia who are at high
risk of progressing to incipient late-onset AD.
The ﬁnal three papers accept the amyloid cascade
hypothesisasamechanisticexplanationforthecharacteristic
neuropathogenesis of late-onset AD, but each develops an
interesting new idea concerning how the accumulation of β-
amyloid at high levels might be initiated and maintained.
The ﬁrst of the three papers reviews the biochemical
roles of the transglutaminase enzymes, the long-standing
hypothesis that the activity of these enzymes contributes to
oligomerization and accumulation of β-amyloid, and posits
that speciﬁc inhibitors of the enzymes found in the CNS may
prove to be eﬀective therapeutic targets to ameliorate disease
progression.
The next paper reports that when Aβ1-42 is infused
into mice, the activity of a particular ABC transport system
is impaired, leading to attenuated removal of β-amyloid
from the brain. This intriguing observation suggests that
the documented age-related decrease in the expression
of that transporter may contribute to the accumulation
of β-amyloid in the brain and thus of NSP formation.
The ﬁnal paper in this special issue is a study of the
function(s) of a noncoding transcript from the BACE1-
encoding gene, using a transgenic mouse model in which Aβ
production is excessive. Previous work from this group had
demonstrated that these noncoding transcripts stabilize the
mRNA specifying BACE1, thereby increasing the production
of insoluble β-amyloid. In the present study, knockdown-
basedinhibitionofeitherthenoncodingorBACE1-encoding
transcript engendered decreased β-amyloid production and
attenuated neuronal degeneration. These last three papers
point to new ways of reducing the burden of NSPs in the
brains of transgenic mice. The challenge now is to determine
if these approaches can be applied to the brains of aging
primates,andifso,whetherreducingtheburdenofNSPswill
be suﬃcient to slow the rate of cognitive decline.
AD and stroke together account for the bulk of cognitive
impairment and mortality worldwide. As the risk factors
and causes of stroke are becoming better understood,
interventions have started to decrease the incidence of
stroke (see, e.g., [1]). By contrast, despite three decades of
intense research, the etiology of late-onset AD remains to
be elucidated, and the incidence of this disease is steadily
increasing (see, e.g., [2]). The present collection of papers
illustrates that progress is being made on several fronts
and indicates that many avenues of enquiry remain to be
explored. We hope that these papers will stimulate new
linesofthinking andexperimentation, therebyhasteningour
understanding of this cruel and insidious disease.
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